Even Lower Doses of Semaglutide Improve Inflammation and Metabolism in Obesity
Submaximal semaglutide doses combined with diet and exercise improved metabolic profiles and reduced inflammation markers in 32 obese patients over 12 weeks.
Quick Facts
What This Study Found
Submaximal doses of semaglutide combined with lifestyle modifications improved metabolic markers and obesity-related inflammation biomarkers over 12 weeks.
Key Numbers
32 patients (11 men, 21 women, mean age 49, mean BMI 40.5). 12-week treatment with submaximal semaglutide. Significant reductions in weight, insulin, leptin, ferritin, resistin, IL-6, TNF-alpha, and PAI-1.
How They Did This
Prospective observational study of 32 adults (11 men, 21 women; mean BMI 40.5; mean age 49) treated with submaximal semaglutide plus hypocaloric diet and increased physical activity over 12 weeks.
Why This Research Matters
Many patients cannot tolerate maximum semaglutide doses due to side effects. Showing that lower doses still provide metabolic benefits gives clinicians confidence to use doses that patients can actually maintain.
The Bigger Picture
This supports a more nuanced approach to GLP-1 dosing — rather than pushing all patients to maximum doses, lower doses combined with lifestyle changes may provide sufficient metabolic improvement with better tolerability.
What This Study Doesn't Tell Us
Small sample (n=32), no control group, and short 12-week duration. Cannot separate the effects of semaglutide from those of diet and exercise changes.
Questions This Raises
- ?How do submaximal dose results compare to full-dose semaglutide outcomes in matched populations?
- ?Are the inflammatory improvements sustained beyond 12 weeks at submaximal doses?
Trust & Context
- Key Stat:
- Mean BMI 40.5 Even in severely obese patients, submaximal semaglutide doses combined with lifestyle changes produced measurable metabolic improvements
- Evidence Grade:
- Observational study without a control group — the improvements could be partly or wholly due to dietary and exercise changes. A randomized controlled trial would be needed for definitive conclusions.
- Study Age:
- Published in 2025, contributing real-world evidence on lower-dose semaglutide effectiveness.
- Original Title:
- Effect of Submaximal Doses of Semaglutide in Patients with Obesity on Metabolic Profile and Serum Levels of Adipocytokines.
- Published In:
- Pharmaceuticals (Basel, Switzerland), 18(9) (2025)
- Authors:
- Péč, Martin Jozef(3), Jurica, Jakub(2), Péčová, Monika, Nagy, Norbert, Focko, Boris, Miertová, Zuzana, Ferencová, Nikola, Ságová, Ivana, Tonhajzerová, Ingrid, Bolek, Tomáš, Galajda, Peter, Mokáň, Marián, Samoš, Matej
- Database ID:
- RPEP-13130
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
Can lower doses of semaglutide still help with obesity?
This study suggests yes. Even submaximal doses improved metabolic and inflammatory markers when combined with diet and exercise, potentially offering a better-tolerated option for patients who cannot handle the full dose.
What are adipocytokines?
Adipocytokines are signaling molecules released by fat tissue that regulate inflammation, metabolism, and appetite. In obesity, these markers are often abnormal, contributing to metabolic dysfunction and chronic low-grade inflammation.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13130APA
Péč, Martin Jozef; Jurica, Jakub; Péčová, Monika; Nagy, Norbert; Focko, Boris; Miertová, Zuzana; Ferencová, Nikola; Ságová, Ivana; Tonhajzerová, Ingrid; Bolek, Tomáš; Galajda, Peter; Mokáň, Marián; Samoš, Matej. (2025). Effect of Submaximal Doses of Semaglutide in Patients with Obesity on Metabolic Profile and Serum Levels of Adipocytokines.. Pharmaceuticals (Basel, Switzerland), 18(9). https://doi.org/10.3390/ph18091364
MLA
Péč, Martin Jozef, et al. "Effect of Submaximal Doses of Semaglutide in Patients with Obesity on Metabolic Profile and Serum Levels of Adipocytokines.." Pharmaceuticals (Basel, 2025. https://doi.org/10.3390/ph18091364
RethinkPeptides
RethinkPeptides Research Database. "Effect of Submaximal Doses of Semaglutide in Patients with O..." RPEP-13130. Retrieved from https://rethinkpeptides.com/research/pec-2025-effect-of-submaximal-doses
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.